{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T03:51:16Z","timestamp":1775361076539,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Isr J Health Policy Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the last twenty years, there was a documented increase in prescription opioid procurement in Israel. However, there is still little evidence of the association between opioid procurement rates, health service utilisation in secondary care, and enrollment rates to substance use disorder treatment programmes. In this study, we show trends in the reports of opioid-related hospitalisations, emergency department visits, enrollment to community-based outpatient treatment for Prescription Opioid Use Disorder and opioid-related mortality rates. Additionally, we examine potential correlations between these\u00a0health service utilisation rates and  prescription opioid procurement rates at the population level,\u00a0with a focus on transdermal fentanyl.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A longitudinal study at the population level. We used seven-year data on indicators of opioid-related morbidity, prescription opioid procurement data for 2015\u20132021, and six-year opioid-related mortality data for 2015\u20132020. We measure the correlation between procurement rates of prescription opioids in Oral Morphine Equivalent per capita, and aggregated rates obtained from hospital administrative data for hospitalisations, emergency department visits, and patient enrolment in specialised prescription opioid use disorder outpatient treatment in the community setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 2015 and 2021, procurement rates in primary care per capita for all prescription opioids increased by 85%, while rates of transdermal fentanyl procurement increased by 162%. We found a significant positive correlation at the population level, between annual opioid procurement rates, and rates per population of opioid-related visits to emergency departments (r\u2009=\u20090.96, <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.01, [CI 0.74\u20130.99]), as well as a positive correlation with the rates per population of patient enrolment in specialised prescription opioid use disorder outpatient treatment (r\u2009=\u20090.93, <jats:italic>p<\/jats:italic> value\u2009=\u20090.02, [CI 0.58\u20130.99]). Opioid-related mortality peaked in 2019 at 0.31 deaths per 100,000 but decreased to 0.20 deaths per 100,000 in 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Data shows that all-opioid and transdermal fentanyl procurement has increased yearly between 2015 and 2021. This increase is positively correlated with a growing demand for community-based Prescription Opioid Use Disorder outpatient treatment. Efforts to reduce opioid-related morbidity may require effective approaches toward appropriate prescribing, monitoring, and further increasing access to prescription opioid outpatient treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13584-023-00558-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:57:11Z","timestamp":1679864231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Trends and correlated outcomes in population-level prescription opioid and transdermal fentanyl use in Israel"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5268-8976","authenticated-orcid":false,"given":"Barak","family":"Shapira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronny","family":"Berkovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziona","family":"Haklai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehama","family":"Goldberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Lipshitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"16","key":"558_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/archinternmed.2010.273","volume":"170","author":"JB Braden","year":"2010","unstructured":"Braden JB, Russo J, Fan MY, Edlund MJ, Martin BC, DeVries A, Sullivan MD, Sullivan M, Sullivan MD. Emergency department visits among recipients of chronic opioid therapy. JAMA Intern Med. 2010;170(16):1425\u201332. https:\/\/doi.org\/10.1001\/archinternmed.2010.273.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"558_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugalcdep.2005.08.019","volume":"82","author":"N Dasgupta","year":"2006","unstructured":"Dasgupta N, Kramer ED, Zalman M-A, Carino S, Smith MY, Haddox JD, Wright C. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend. 2006;82(2):135\u201342. https:\/\/doi.org\/10.1016\/j.drugalcdep.2005.08.019.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"558_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2105\/ajph.2019.305045","volume":"109","author":"EA Samuels","year":"2019","unstructured":"Samuels EA. Emergency departments as barometers for prescription opioid morbidity and mortality. Am J Public Health. 2019;109(5):655\u20136. https:\/\/doi.org\/10.2105\/ajph.2019.305045.","journal-title":"Am J Public Health"},{"issue":"1","key":"558_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejp.1291","volume":"23","author":"C Chenaf","year":"2019","unstructured":"Chenaf C, Kabore J-L, Delorme J, Pereira B, Pereira B, Pereira B, Mulliez A, Mulliez A, Zenut M, Delage N, Ardid D, Eschalier A, Authier N. Prescription opioid analgesic use in France: trends and impact on morbidity\u2013mortality. Eur J Pain. 2019;23(1):124\u201334. https:\/\/doi.org\/10.1002\/ejp.1291.","journal-title":"Eur J Pain"},{"key":"558_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ypmed.2018.09.001","volume":"116","author":"B Fischer","year":"2018","unstructured":"Fischer B, Jones W, Varatharajan T, Malta M, Malta M, Malta M, Kurdyak P. Correlations between population-levels of prescription opioid dispensing and related deaths in Ontario (Canada), 2005\u20132016. Prev Med. 2018;116:112\u20138. https:\/\/doi.org\/10.1016\/j.ypmed.2018.09.001.","journal-title":"Prev Med"},{"key":"558_CR6","doi-asserted-by":"publisher","first-page":"108830","DOI":"10.1016\/j.drugalcdep.2021.108830","volume":"225","author":"S Kitchen","year":"2021","unstructured":"Kitchen S, McCormack D, Werb D, Caudarella A, Martins D, Matheson FI, Gomes T, Gomes T. Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada. Drug Alcohol Depend. 2021;225:108830\u2013108830. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108830.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"558_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/17512433.2022.2114898","volume":"15","author":"A Bedene","year":"2022","unstructured":"Bedene A, Dahan A, Rosendaal FR, van Dorp ELA. Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids. Expert Rev Clin Pharmacol. 2022;15(9):1081\u201394. https:\/\/doi.org\/10.1080\/17512433.2022.2114898.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"558_CR8","doi-asserted-by":"publisher","first-page":"117863291881944","DOI":"10.1177\/1178632918819440","volume":"11","author":"SA Bernard","year":"2018","unstructured":"Bernard SA, Chelminski PR, Ives TJ, Ranapurwala SI. Management of Pain in the United States\u2014a brief history and implications for the opioid epidemic. Health Serv Insights. 2018;11:1178632918819440. https:\/\/doi.org\/10.1177\/1178632918819440.","journal-title":"Health Serv Insights"},{"key":"558_CR9","unstructured":"Substance Abuse and Mental Health Services Administration [SAMHSA]. 2020 National Survey of Drug Use and Health (NSDUH) Releases. US Department of Health and Human Services; 2021. https:\/\/www.samhsa.gov\/data\/release\/2020-national-survey-drug-use-and-health-nsduh-releases."},{"issue":"1","key":"558_CR10","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1192\/j.eurpsy.2021.2219","volume":"64","author":"M Pierce","year":"2021","unstructured":"Pierce M, van Amsterdam J, Kalkman GA, Schellekens A, van den Brink W. Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. Eur Psychiatry. 2021;64(1):e47. https:\/\/doi.org\/10.1192\/j.eurpsy.2021.2219.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"558_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11096-020-01205-y","volume":"43","author":"A Alenezi","year":"2021","unstructured":"Alenezi A, Yahyouche A, Paudyal V. Current status of opioid epidemic in the United Kingdom and strategies for treatment optimisation in chronic pain. Int J Clin Pharm. 2021;43(2):318\u201322. https:\/\/doi.org\/10.1007\/s11096-020-01205-y.","journal-title":"Int J Clin Pharm"},{"key":"558_CR12","unstructured":"Centers for Disease Control and Prevention [CDC]. Vital statistics rapid release\u2014provisional drug overdose data; 2021. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"issue":"5","key":"558_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jamapsychiatry.2020.4218","volume":"78","author":"J Friedman","year":"2021","unstructured":"Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiat. 2021;78(5):562. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.4218.","journal-title":"JAMA Psychiat"},{"key":"558_CR14","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.drugalcdep.2020.108176","volume":"214","author":"S Slavova","year":"2020","unstructured":"Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108176.","journal-title":"Drug Alcohol Depend"},{"key":"558_CR15","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.jsat.2021.108391","volume":"129","author":"JM Pines","year":"2021","unstructured":"Pines JM, Zocchi MS, Black BS, Carlson JN, Celedon P, Moghtaderi A, Venkat A. How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic. J Subst Abuse Treat. 2021;129:108391. https:\/\/doi.org\/10.1016\/j.jsat.2021.108391.","journal-title":"J Subst Abuse Treat"},{"key":"558_CR16","unstructured":"Office for National Statistics [ONS]. Deaths related to drug poisoning in England and Wales: 2020 registrations. UK Data Service; 2021. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2020."},{"issue":"12","key":"558_CR17","first-page":"928","volume":"146","author":"T Freud","year":"2007","unstructured":"Freud T, Brill S, Sherf M, Singer Y, Vardy D, Shvartzman P. Trend in opioids use for chronic pain treatment at Clalit Health Services (2000\u20132004). Harefuah. 2007;146(12):928\u201331.","journal-title":"Harefuah"},{"issue":"5","key":"558_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/rapm-2020-101924","volume":"46","author":"O Miron","year":"2020","unstructured":"Miron O, Zeltzer D, Shir T, Balicer RD, Einav L, Feldman B. Rising opioid prescription fulfillment among non-cancer and non-elderly patients-Israel\u2019s alarming example. Reg Anesth Pain Med. 2020;46(5):455\u20136. https:\/\/doi.org\/10.1136\/rapm-2020-101924.","journal-title":"Reg Anesth Pain Med"},{"key":"558_CR19","doi-asserted-by":"publisher","unstructured":"Miron O, Barda N, Balicer R, Kor A, Lev-Ran S. Association of opioid use disorder with healthcare utilisation and cost in a public health system. Addiction. 2022. https:\/\/doi.org\/10.1111\/add.15963.","DOI":"10.1111\/add.15963"},{"issue":"6","key":"558_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000485033","volume":"23","author":"D Feingold","year":"2017","unstructured":"Feingold D, Goldberger N, Haklai Z, Lev-Ran S. Fatal overdoses of opioids in Israel 2005\u20132014. Eur Addict Res. 2017;23(6):276\u201383. https:\/\/doi.org\/10.1159\/000485033.","journal-title":"Eur Addict Res"},{"key":"558_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2021.1922609","author":"B Shapira","year":"2021","unstructured":"Shapira B, Rosca P. Mountain or molehill? A scoping review of evidence on an opioid use problem in Israel. Drugs Educ Prev Policy. 2021. https:\/\/doi.org\/10.1080\/09687637.2021.1922609.","journal-title":"Drugs Educ Prev Policy."},{"key":"558_CR22","unstructured":"Pilote A. The Health Ministry is on its way to stop the opioid epidemic. Calcalist; 2019. https:\/\/www.calcalist.co.il\/local\/articles\/0,7340,L-3758386,00.html."},{"key":"558_CR23","unstructured":"Rosca P, Spivak P, Goldman K, Austin O. Summary of the activity of the Department for the treatment of addictions for year 2019; 2020. https:\/\/www.health.gov.il\/UnitsOffice\/HD\/MHealth\/mental\/addictions\/Documents\/mtl-addictions-2019.pdf."},{"key":"558_CR24","unstructured":"Israel Ministry of Health. Specialised programmes for treating dependence (addiction) to pain relievers. Israel Ministry of Health; 2018. https:\/\/www.gov.il\/BlobFolder\/generalpage\/prescription-drugs\/he\/files_publications_subjects_addictions_opioids-misuse.pdf."},{"issue":"4","key":"558_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/yco.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350. https:\/\/doi.org\/10.1097\/yco.0000000000000717.","journal-title":"Curr Opin Psychiatry"},{"key":"558_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drugpo.2019.04.010","volume":"70","author":"M Zoorob","year":"2019","unstructured":"Zoorob M. Fentanyl shock: the changing geography of overdose in the United States. Int J Drug Policy. 2019;70:40\u20136. https:\/\/doi.org\/10.1016\/j.drugpo.2019.04.010.","journal-title":"Int J Drug Policy"},{"key":"558_CR27","unstructured":"Dolev D. The prescription plague: One in 10 Israelis in danger of opioid addiction. Hashomrim. 2021. https:\/\/www.hashomrim.org\/eng\/381."},{"key":"558_CR28","unstructured":"Israel Knesset. The Special Committee on Drugs and Addiction: Health Ministry: Doctors provide prescriptions under threat; 2022. https:\/\/main.knesset.gov.il\/News\/PressReleases\/Pages\/press01062022J.aspx."},{"key":"558_CR29","unstructured":"Israel Ministry of Health. Call for proposal-consultation with the public regarding regulatory changes in prescribing of opioids; 2022. https:\/\/www.pharmaline.co.il\/tag\/%D7%9E%D7%A9%D7%A8%D7%93-%D7%94%D7%91%D7%A8%D7%99%D7%90%D7%95%D7%AA\/."},{"issue":"5","key":"558_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/0310057X1404200504","volume":"42","author":"PE Macintyre","year":"2014","unstructured":"Macintyre PE, Huxtable CA, Flint SLP, Dobbin MDH. Costs and consequences: a review of discharge opioid prescribing for ongoing management of acute pain. Anaesth Intensive Care. 2014;42(5):558\u201374. https:\/\/doi.org\/10.1177\/0310057X1404200504.","journal-title":"Anaesth Intensive Care"},{"key":"558_CR31","unstructured":"Movement for Freedom of Information. Israeli Health Maintainance Organizations reveal for the first time the extent of opioid use; 2022. https:\/\/www.meida.org.il\/12224."},{"issue":"6","key":"558_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/pds.3945","volume":"25","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016;25(6):733\u20137. https:\/\/doi.org\/10.1002\/pds.3945.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"558_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.puhe.2012.04.010","volume":"126","author":"B Fischer","year":"2012","unstructured":"Fischer B, Nakamura N, Urbanoski K, Rush B, Rehm J. Correlations between population levels of prescription opioid use and prescription-opioid-related substance use treatment admissions in the USA and Canada since 2001. Public Health. 2012;126(9):749\u201351. https:\/\/doi.org\/10.1016\/j.puhe.2012.04.010.","journal-title":"Public Health"},{"issue":"4","key":"558_CR34","doi-asserted-by":"publisher","first-page":"e0250320","DOI":"10.1371\/journal.pone.0250320","volume":"16","author":"N Hardy","year":"2021","unstructured":"Hardy N, Zeba F, Ovalle A, Yanac A, Nzugang-Noutonsi C, Abadier M, Ovalle A, Chahin A. Association of prescription opioid use on mortality and hospital length of stay in the intensive care unit. PLoS ONE. 2021;16(4):e0250320. https:\/\/doi.org\/10.1371\/journal.pone.0250320.","journal-title":"PLoS ONE"},{"key":"558_CR35","unstructured":"Koch Davidovich Flora F. The Issue of continuum of care in the addictions treatment system and its relationship with the mental health services. Knesset Research and Information Centre; 2021. https:\/\/fs.knesset.gov.il\/globaldocs\/MMM\/94b70348-2428-eb11-811a-00155d0af32a\/2_94b70348-2428-eb11-811a-00155d0af32a_11_18013.pdf."},{"issue":"6","key":"558_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5811\/westjem.2020.8.48632","volume":"21","author":"AD Lucero","year":"2020","unstructured":"Lucero AD, Lee A, Hyun J, Lee C, Kahwaji C, Miller G, Neeki M, Tamayo-Sarver J, Pan L. Underutilisation of the emergency department during the COVID-19 pandemic. West J Emerg Med. 2020;21(6):15\u201323. https:\/\/doi.org\/10.5811\/westjem.2020.8.48632.","journal-title":"West J Emerg Med"},{"key":"558_CR37","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.drugpo.2020.102830","volume":"83","author":"P Rosca","year":"2020","unstructured":"Rosca P, Shapira B, Neumark Y. Isolating the isolated: Implications of COVID-19 quarantine measures on inpatient detoxification treatment for substance use disorders. Int J Drug Policy. 2020;83:102830. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102830.","journal-title":"Int J Drug Policy"},{"key":"558_CR38","doi-asserted-by":"publisher","first-page":"101198","DOI":"10.1016\/j.eclinm.2021.101198","volume":"42","author":"S Jayawardana","year":"2021","unstructured":"Jayawardana S, Forman R, Johnston-Webber C, Campbell A, Berterame S, de Joncheere C, Aitken M, Mossialos E. Global consumption of prescription opioid analgesics between 2009\u20132019: a country-level observational study. EClinicalMedicine. 2021;42:101198. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101198.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"558_CR39","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/S2468-2667(22)00013-5","volume":"7","author":"C Ju","year":"2022","unstructured":"Ju C, Wei L, Man KKC, Wang Z, Ma T-T, Chan AYL, Brauer R, Chui CSL, Chan EW, Jani YH, Hsia Y, Wong ICK, Lau WCY. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Health. 2022;7(4):e335\u201346. https:\/\/doi.org\/10.1016\/S2468-2667(22)00013-5.","journal-title":"Lancet Public Health"},{"key":"558_CR40","unstructured":"International Narcotics Control Board. Narcotic Drugs\u2014Estimated World Requirements for 2022\u2014Statistics for 2020 (E\/INCB\/2021\/1); 2022. https:\/\/www.incb.org\/documents\/Narcotic-Drugs\/Technical-Publications\/2021\/Narcotic_Drugs_Technical_Publication_2021.pdf."},{"key":"558_CR41","doi-asserted-by":"publisher","first-page":"xi51","DOI":"10.1093\/annonc\/mdt503","volume":"24","author":"J Cleary","year":"2013","unstructured":"Cleary J, Silbermann M, Scholten W, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in the Middle East: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol. 2013;24:xi51\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdt503.","journal-title":"Ann Oncol"},{"issue":"5","key":"558_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/pds.4415","volume":"27","author":"AM Ponizovsky","year":"2018","unstructured":"Ponizovsky AM, Marom E, Weizman A, Schwartzberg E. Changes in consumption of opioid analgesics in Israel 2009 to 2016: an update focusing on oxycodone and fentanyl formulations. Pharmacoepidemiol Drug Saf. 2018;27(5):535\u201340. https:\/\/doi.org\/10.1002\/pds.4415.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"558_CR43","unstructured":"[Dangerous Drugs Regulations], Pub. L. No. 4047; 1979."},{"key":"558_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1754534","author":"B Shapira","year":"2020","unstructured":"Shapira B, Berkovitz R, Rosca P, Neumark Y. Recent use of synthetic cannabinoids, synthetic opioids, and other psychoactive drug groups among high-risk drug users. J Psychoact Drugs. 2020. https:\/\/doi.org\/10.1080\/02791072.2020.1754534.","journal-title":"J Psychoact Drugs"},{"key":"558_CR45","unstructured":"Centers for Disease Control and Prevention [CDC]. Opioid prescribing guideline resources; 2021. https:\/\/www.cdc.gov\/drugoverdose\/prescribing\/resources.html."},{"key":"558_CR46","unstructured":"Israeli Medical Association. Treatment with opioids in non-cancer pain; 2016. https:\/\/www.ima.org.il\/userfiles\/image\/Ne76_opyoidim.pdf."},{"key":"558_CR47","unstructured":"Israel Ministry of Health. Assessment, monitoring, and rational use of opioid formulation for the treatment of non cancer pain; 2022. https:\/\/www.gov.il\/he\/departments\/policies\/mr009-2022."},{"key":"558_CR48","unstructured":"Center for Drug Evaluation and Research. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualised tapering. FDA. 2019. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes."},{"issue":"4","key":"558_CR49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/acem.13121","volume":"24","author":"C Rowe","year":"2017","unstructured":"Rowe C, Vittinghoff E, Santos G-M, Behar E, Turner C, Coffin PO. Performance measures of diagnostic codes for detecting opioid overdose in the emergency department. Acad Emerg Med. 2017;24(4):475\u201383. https:\/\/doi.org\/10.1111\/acem.13121.","journal-title":"Acad Emerg Med"},{"key":"558_CR50","doi-asserted-by":"publisher","first-page":"108537","DOI":"10.1016\/j.drugalcdep.2021.108537","volume":"221","author":"CL Rowe","year":"2021","unstructured":"Rowe CL, Santos G-M, Kornbluh W, Bhardwaj S, Faul M, Coffin PO. Using ICD-10-CM codes to detect illicit substance use: a comparison with retrospective self-report. Drug Alcohol Depend. 2021;221:108537. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108537.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"558_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1186\/s12913-018-3756-8","volume":"18","author":"R Di Rico","year":"2018","unstructured":"Di Rico R, Nambiar D, Stoov\u00e9 M, Dietze P. Drug overdose in the ED: a record linkage study examining emergency department ICD-10 coding practices in a cohort of people who inject drugs. BMC Health Serv Res. 2018;18(1):945. https:\/\/doi.org\/10.1186\/s12913-018-3756-8.","journal-title":"BMC Health Serv Res"}],"container-title":["Israel Journal of Health Policy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-023-00558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13584-023-00558-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-023-00558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T21:02:31Z","timestamp":1679864551000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijhpr.biomedcentral.com\/articles\/10.1186\/s13584-023-00558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1186\/s13584-023-00558-9","relation":{},"ISSN":["2045-4015"],"issn-type":[{"value":"2045-4015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}